Oasmia Pharmaceutical AB (publ) (OM:OASM) will look for merger and acquisition opportunities. During an update on the company's third quarter and year-end results conference call, Francois Martelet said that ‘the cash position is strong, that will help us, obviously, to pursue high-value licensing in and/or M&A opportunities’.